UPDATE: Evercore ISI Starts Inhibrx Inc. (INBX) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stock futures fall as fading Iran peace prospects drive up oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Credit Suisse Starts Inhibrx Inc. (INBX) at Outperform
September 14, 2020 5:05 AM EDTCredit Suisse analyst Martin Auster initiates coverage on Inhibrx Inc. (NASDAQ: INBX) with a Outperform rating and a price target of $26.00.
The analyst comments "Inhibrx is an emerging oncology/rare disease company with four clinical-stage assets. INBRX-109 is the most advanced asset... More
